The patent pertains to an optimized vector structure designed for the large-scale production of replication-incompetent adenoviruses. This achievement follows similar patent approvals in South Korea, the United States, China, Japan, and Russia, with applications still under review in Vietnam, Indonesia, Thailand, and Brazil.
In the production of replication-incompetent adenoviral vectors, unintended generation of replication-competent adenoviruses can compromise product quality. Global pharmaceutical companies often address this issue by developing specialized producer cell lines or using alternative adenovirus serotypes, but these approaches carry high costs and risks of dependency on foreign technologies.
Cellid’s patented technology reduces reliance on overseas platforms, establishing a foundation for not only its COVID-19 variant-targeted vaccine but also its BVAC immuno-oncology therapies.
“This European patent underscores the global recognition of our proprietary technology’s value,” said Chang-Yul Kang, CEO of Cellid. “It enhances the quality and safety of our vaccines and strengthens South Korea’s domestic vaccine platform.”
Kang also highlighted the urgency of their work amid signs of COVID-19 resurgence in Asia and South Korea. “With Phase 3 clinical trial dosing completed, we are accelerating preparations for regulatory approval of our vaccine,” he said. “Through commercialization, we aim to bolster national vaccine sovereignty.”
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
